Swayampakula Ramakanth

Lucy-Emma Codrington-Bartlett

Clément Bassat

Clement Sears

Elliott Bosco

Jonathan Chang

Lucy Codrington

Michael Schmidt

Shan Hama

Xiaochuan Dai

Yen-Der Li

Yihan Li

- Nanobiotix S.A. reported new Phase 1 study results for **JNJ-1900 (NBTXR3)** in combination with immune checkpoint inhibitors for patients with primary cutaneous melanoma resistant to anti-PD-1, demonstrating a **favorable safety profile** and **early efficacy signals**.  **[1760854_0001171843-25-005941_exh_991.htm:0]** 
- As of the **August 21, 2025**, data cutoff, the study showed a **47.4% (9/19) objective response rate (ORR)** and a **78.9% (15/19) disease control rate (DCR)** in all lesions for evaluable patients.  **[1760854_0001171843-25-005941_exh_991.htm:0]** **[1760854_0001171843-25-005941_exh_991.htm:1]** 
- The median Overall Survival (mOS) for all **21 treated patients** was **14.6 months**, with investigators concluding the data warrant further investigation in randomized clinical trials.  **[1760854_0001171843-25-005941_exh_991.htm:0]** **[1760854_0001171843-25-005941_exh_991.htm:1]**

Nanobiotix Announces Positive Phase 1 Study Results for JNJ-1900 (NBTXR3)

Nanobiotix (NBTX)